Sodium cromoglycate and nedocromil sodium in the therapy of asthma, a critical comparison

Pulmonary Pharmacology

Volumn 9, Issue 2, 1996, Pages 95-105

  Parnham, M J ^a  

^a PAS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; KETOTIFEN; NEDOCROMIL SODIUM; OXYGEN RADICAL;

ADULT; ASTHMA; B LYMPHOCYTE; CHEMOTAXIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; EOSINOPHIL; EXERCISE INDUCED ASTHMA; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATORY CELL; INHALATIONAL DRUG ADMINISTRATION; LEUKOCYTE; LUNG; LUNG FUNCTION; MAJOR CLINICAL STUDY; MAST CELL; META ANALYSIS; NEUROGENIC INFLAMMATION; NEUTROPHIL; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD; T LYMPHOCYTE; THROMBOCYTE;

EID: 0030127217     PISSN: 09520600     EISSN: None     Source Type: Journal    
DOI: 10.1006/pulp.1996.0011     Document Type: Review

References (82)

1. 1. Murphy S, Kelly H W. Cromolyn sodium: a review of mechanisms and clinical use in asthma. Drug Intell Clin Pharm 1987; 21: 22-35.
2. 2. Meltzer E O. An overview of current pharmacotherapy in perennial rhinitis. J Allergy Clin Immunol 1995; 95: 1097-1110.
3. 3. Asthma Consensus Group. Asthma: a follow up statement from an international pediatric asthma consensus group. Br Med J 1992; 67: 240-248.
4. 4. Rainey D K. Background and objectives of the basic research programme for nedocromil sodium. Drugs 1989; 37 (Suppl 1): 1-3.
5. 5. Brogden R N, Sorkin E M. Nedocromil sodium. An updated review of its pharmacological properties and therapeutic efficacy in asthma. Drugs 1993; 45: 693-715.
6. 6. Church M K. Is inhibition of mast cell mediator release relevant to the clinical activity of anti-allergic drugs? Agents Actions 1986; 18: 288-293.
7. εRII). Int J Immunopharmacol 1988; 10: 227-236.
8. 8. Edwards A M. Sodium cromoglycate (Intal®) as an anti-inflammatory agent for the treatment of chronic asthma. Clin Exp Allergy 1994; 24: 612-623.
9. 9. Okayama Y, Benyon R C, Rees P H, Lowman M A, Millier K, Church M K. Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine. Clin Exp Allergy 1992; 22: 401-409.
10. 10. Leung K B P, Flint K C, Brostoff J, Hudspith B N, Johnson N McI, Lau H Y A, Liu W L, Pearce F L. Effects of sodium cromoglycate and nedocromil sodium on histamine secretion from human lung mast cells. Thorax 1988; 43: 756-761.
11. 2 release from primate bronchoalveolar mast cells and a comparison with rat peritoneal mast cells. J Immunol 1986; 127: 3941-3945.
12. 12. Eady R P, Greenwood B, Jackson D M, Orr T S C, Wells E. The effect of nedocromil sodium and sodium cromoglycate on antigen-induced bronchoconstriction in the Ascaris-sensitive monkey. Br J Pharmacol 1985; 85: 323-325.
13. 13. Abraham W M, Stevenson J S, Sielczak M S. Preliminary report on the effect of nedocromil sodium on antigen-induced early and late reactions in allergic sheep. Eur J Resp Dis 1986; 69 (Suppl 147): 192-195.
14. 14. Fuller R W, Macdermot J. Stimulation of IgE sensitized human alveolar macrophages by anti-IgE is unaffected by sodium cromoglycate. Clin Allergy 1986; 16: 523-526.
15. 15. Moqbel R, Cromwell O, Walsh G M, Wardlaw A J, Kurlak L, Kay A B. Effects of nedocromil sodium (Tilade®) on the activation of human eosinophils and neutrophils and the release of histamine from mast cells. Allergy 1988; 43: 268-276.
16. 16. Joseph M, Thorel T, Tsicopoulos A, Tonnel A B, Capron A. Nedocromil sodium inhibition of IgE-mediated activation of human mononuclear phagocytes and platelets from asthmatics. Drugs 1989; 37 (Suppl 1): 32-36.
17. 17. Marquette C H, Joseph M, Tonnel A B, Vorng H, Lassalle P, Tsicopoulos A, Capron A. The abnormal in vitro response to aspirin of platelets from aspirin-sensitive asthmatics is inhibited after inhalation of nedocromil sodium but not of sodium cromoglycate. Br J Clin Pharmac 1990; 29: 525-531.
18. 4-induced basophil degranulation. Drugs 1989; 37 (Suppl 1): 4-8.
19. 4 generation by human eosinophils stimulated by ionophore or unopsonized zymosan. J Allergy Clin Immunol 1989; 83: 206.
20. 20. Bruijnzeel P L B, Warringa R A J, Kok P T M, Kreukniet J. Inhibition of neutrophil and eosinophil induced chemotaxis by nedocromil sodium and sodium cromoglycate. Br J Pharmacol 1990; 99: 798-802.
21. 21. Rubin R P, Thompson R H, Naps M S. Differential inhibition by nedocromil sodium of superoxide generation by platelet activating factor in human neutrophils. Agents Actions 1990; 31: 237-242.
22. 22. Peroni D G, Melotti P, Piacentini G L, Bonizzato C, Boner A L. Effects of nedocromil sodium on the binding of N-formyl-methionyl-leucyl-phenylalanine in human neutrophils. Agents Actions 1992; 36: 212-214.
23. 23. Hutson P A, Holgate S T, Church M K. Inhibition by nedocromil sodium of early and late phase bronchoconstriction and airway cellular infiltration provoked by ovalbumin inhalation in conscious sensitized guinea-pigs. Br J Pharmacol 1988; 94: 6-8.
24. 24. Schellenberg R R, Ishida K, Thomson R J. Nedocromil sodium inhibits airway hyperresponsiveness and eosinophilic infiltration induced by repeated antigen challenge in guinea-pigs. Br J Pharmacol 1991; 103: 1842-1846.
25. 25. Barnes P J. New aspects of asthma. J Internal Med 1992; 231: 453-461.
26. 26. Loh R K, Jabara H H, Geha R S. Disodium cromoglycate inhibits Sμ→Sε deletional switch recombination and IgE synthesis in human B cells. J Exp Med 1994; 180: 663-671.
27. 4 production by human B cells in vitro. Clin Exp Immunol 1991; 84: 395-399.
28. 27a. Diaz P, Galleguillos F R, Gonzalez M C, Pentin C F A, Kay A B. Bronchoalveolar lavage in asthma: the effect of disodium cromoglycate (cromolyn) on leukocyte counts, immunoglobulins, and complement. J Allergy Clin Immunol 1984; 74: 41-48.
29. 28. Heinke S, Szücs G, Norris A, Droogmans G, Nilius B. Inhibition of volume-activated chloride currents in endothelial cells by chromones. Br J Pharmacol 1995; 115: 1393-1398.
30. 29. Dixon M, Jackson D M, Richards I M. The action of sodium cromoglycate on "C" fibre endings in the dog lung. Br J Pharmacol 1980; 70: 11-13.
31. 30. Norris A A, Leeson M L, Jackson D M, Holroyde M C. Modulation of neurogenic inflammation in rat trachea. Pulmonary Pharmacol 1990; 3: 180-184.
32. 31. Crossman D C, Dashwood M R, Taylor G W, Wellings R, Fuller R W. Sodium cromoglycate: evidence of tachykinin antagonist activity in human skin. J Appl Physiol 1993; 75: 167-172.
33. 32. Page C. Sodium cromoglycate, a tachykinin antagonist? Lancet 1994; 343: 70.
34. 33. Parnham M J, Dickenson A H. Developments and clinical leads in nonopioid analgesics. Analgesia 1996; 2: 43-56.
35. 34. Leza J C, Lizasoain I, San Martin-Clark O, Lorenzo P. Role of sodium cromoglycate on analgesia, locomotor activity and opiate withdrawal in mice. Psychopharmacology 1992; 107: 595-600.
36. 35. Jackson D M, Norris A A, Eady R P. Nedocromil sodium and sensory nerves in the dog lung. Pulmonary Pharmacol 1989; 2: 179-184.
37. 36. Joos G F, Pauwels R A, Van der Straeten M E. Effect of nedocromil sodium on the bronchoconstrictor effect of neurokinin A in asthmatics. Drugs 1989; 37 (Suppl 1): 109-112.
38. 37. Dixon C M S, Barnes P J. Bradykinin-induced bronchoconstriction: inhibition by nedocromil sodium and sodium cromoglycate. Br J Clin Pharmacol 1989; 27: 831-836.
39. 38. Gonzalez J P, Brogden R N. Nedocromil sodium. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of reversible obstructive airways disease. Drugs 1987; 34: 560-577.
40. 39. König P, Hordvik N L, Kreutz C. The preventive effect and duration of action of nedocromil sodium and cromolyn sodium on exercise-induced asthma in adults. J Allergy Clin Immunol 1987; 79: 64-68.
41. 40. Patel K R, Albazzaz M K. Protective effect of cromolyn sodium and nedocromil sodium in exercise-induced asthma. J Allergy Clin Immunol 1987; 79: 187.
42. 41. Cavagni G, Caffarelli C, Bertolini P, Giordano S. Comparison of sodium cromoglycate (SCG) with nedocromil (N) in exercise-induced bronchospasm (EIB) in children. Ann Allergy 1992; 68: 95.
43. 42. Morton A R, Ogle S E, Fritch K D. Effects of nedocromil sodium, cromolyn sodium, and a placebo in exercise-induced asthma. Ann Allergy 1992; 68: 143-148.
44. 43. Comis A, Valletta E A, Sette L, Andreoli A, Boner A L. Comparison of nedocromil sodium and sodium cromoglycate administered by pressurized aerosol, with and without a spacer device in exercise-induced asthma in children. Eur Respir J 1993; 6: 523-526.
45. 44. De Benedictis F M, Tuteri G, Bertotto A, Bruni L, Vaccaro R. Comparison of the protective effects of cromolyn sodium and nedocromil sodium in the treatment of exercise-induced asthma in children. J Allergy Clin Immunol 1994; 94: 684-688.
46. 45. Novembre E, Frongia G F, Veneruso G, Vierucci A. Inhibition of exercise-induced asthma (EIA) by nedocromil sodium and sodium cromoglycate in children. Ped Allergy Immunol 1994; 5: 107-110.
47. 46. Juniper E F, Kline P A, Morris M M, Hargreave F E. Airway constriction by isocapnic hyperventilation of cold, dry air: comparison of magnitude and duration of protection by nedocromil sodium and sodium cromoglycate. Clin Allergy 1987; 17: 523-528.
48. 47. Del Bufalo C, Fasano L, Patalano F, Gunella G. Inhibition of fog-induced bronchoconstriction by nedocromil sodium and sodium cromoglycate in intrinsic asthma: a double-blind, placebo-controlled study. Respiration 1989; 55: 181-185.
49. 48. Orefice U, Struzzo P, Dorigo R, Peratoner A. Long-term treatment with sodium cromoglycate, nedocromil sodium and beclomethasone dipropionate reduces bronchial hyperresponsiveness in asthmatic subjects. Respiration 1992; 59: 97-101.
50. 49. van Essen-Zandvliet E E M, Kerrebijn K F. The effect of antiasthma drugs on bronchial hyperresponsiveness. Immunol Allergy Clin N Amer 1990; 10: 483-501.
51. 50. Altounyan R E C, Cole M, Lee T B. Inhibition of sulphur dioxide-induced bronchoconstriction by nedocromil sodium and sodium cromoglycate in non-asthmatic atopic subjects. Eur J Resp Dis 1986; 69 (Suppl 147): 274-276.
52. 51. Wright W, Zhang Y G, Salome C M, Woolcock A J. Effect of inhaled preservatives on asthmatic subjects. 1. Sodium metabisulfite. Am Rev Resp Dis 1990; 141: 1400-1404.
53. 52. Rocchiccioli K M S, Riley P A. Clinical pharmacology of nedocromil sodium. Drugs 1989; 37 (Suppl 1): 123-126.
54. 53. Roberts A M, Hahn H L, Schulz H D, Nadel J A, Coleridge H M et al. Afferent C-fibres are responsible for the reflex airway constriction and secretion evoked by pulmonary administration of sulphur dioxide in dogs. Physiologist 1983; 25: 226.
55. 54. Eady R P, Jackson D M. The effect of nedocromil sodium on citric acid induced cough in conscious dogs. Am Rev Resp Dis 1987; 135: A389.
56. 55. Chan-Yeung M, Malo J-L. Occupational asthma. New Engl J Med 1995; 333: 107-112.
57. 56. Phillips G D, Holgate S T. The mechanism of adenosine-induced bronchoconstriction in asthma. ISI Atlas of Science: Pharmacol 1988; 2: 28-32.
58. 57. Crimi N, Palermo F, Oliveri R, Cacopardo B, Vancheri C, Mistretta A. Adenosine-induced bronchoconstriction: comparison between nedocromil sodium and sodium cromoglycate. Eur J Resp Dis 1986; 69 (Suppl 147): 258-262.
59. 58. Crimi N, Palermo F, Oliveri R, Vancheri C, Polosa R, Palermo B, Maccarrone C, Mistretta A. Comparative study of the effects of nedocromil sodium (4 mg) and sodium cromoglycate (10 mg) on adenosine-induced bronchoconstriction in asthmatic subjects. Clin Allergy 1988; 18: 367-374.
60. 59. Richards R, Phillips G D, Holgate S T. Nedocromil sodium is more potent than sodium cromoglycate against AMP-induced bronchoconstriction in atopic asthma subjects. Clin Exp Allergy 1989; 19: 285-291.
61. 60. McFadden E R, Gilbert I A. Asthma. New Engl J Med 1992; 327: 1928-1937.
62. 61. Petro W, Hamm Th, Bauer P C, Konietzko N. Protektion des Allergen-provozierten Asthma. Vergleich zwischen Nedocromil-Natrium, Dinatrium cromoglicium und Plazebo. Atemw-Lungenkrkh 1986; 12 (Suppl 2): S101-S105.
63. 62. Knotterus I, Pelikan Z. The effects of cromolyn (DSCG) nedocromil (NS) and budesonide (BUD) on the early (EAR) and the late (LAR) asthmatic response, inhaled before and after allergen challenge. J Allergy Clin Immunol 1994; 93: 198.
64. 63. Dickson W, Cole M. Severe asthma in children - a 10 year follow-up. In: Pepys J, Edwards A M eds. The Mast Cell: Its Role in Health and Disease. London: Pitman Medical 1979: 343-352.
65. 64. Lal S, Dorow P D, Venho K K, Chatterjee S S. Nedocromil sodium is more effective than cromolyn sodium for the treatment of chronic reversible obstructive airway disease. Chest 1993; 104: 438-447.
66. 65. Carrasco E, Sepulveda R. Comparison of 1 mg and 5 mg sodium cromoglycate metered dose inhalers in the treatment of asthma: a 12-week, double-blind, parallel group trial. Curr Med Res Opin 1989; 11: 341-353.
67. 66. Svendsen U G. Treatment of bronchial hyperresponsiveness in adults. In: Godard Ph, Bousquet J, Michel F B eds. Advances in Allergology and Clinical Immunology. Carnforth: Parthenon 1992: 569-583.
68. 67. Boldy D A R, Ayres J G. Nedocromil sodium and sodium cromoglycate in patients aged over 50 years with asthma. Resp Med 1993; 87: 517-523.
69. 68. Jones P W. Nedocromil Sodium Quality of Life Study Group. Quality of life, symptoms and pulmonary function in asthma: long-term treatment with nedocromil sodium examined in a controlled multicentre trial. Eur Respir J 1994; 7: 55-62.
70. 69. König P. The risks and benefits of inhaled antiinflammatory therapy in children. In: Schöni M H, Kraemer R eds. Update on Childhood Asthma. Basel: Birkhäuser, Agents Actions Suppl 1993; 40: 181-188.
71. 1-Antihistamines as broad-spectrum drugs for the treatment of various allergic disorders. In: Langer S Z, Church M K, Vargaftig B B, Nicosia S eds. New Developments in the Therapy of Allergic Disorders and Asthma. Basel: Karger, Int Acad Biomed Drug Res 1993; 6: 55-59.
72. 71. Thomson N C. Anti-inflammatory therapies. Br Med Bull 1991; 48: 205-220.
73. 72. Kerrebijn K F. Ketotifen for long-term control of asthma in children. J Allergy Clin Immunol 1990; 86: 274-275.
74. 73. Cockcroft D W, Keshmiri M, Murdock K Y, Gore B C. Allergen-induced increase in airway responsiveness is not inhibited by acute treatment with ketotifen or clemastine. Ann Allergy 1992; 68: 245-250.
75. 74. Orefice U, Struzzo P L, Pitzalis G. Management of childhood allergic bronchial asthma with sodium cromoglycate and ketotifene. Am Rev Resp Dis 1990: 141: A900.
76. 75. Kehnscherper M. DNCG (acecromol®) und Ketotifen (Zatofug®) in der Behandlung von Kindern mit Asthma bronchiale. Kinderärztl Praxis 1993; 61: 276-278.
77. 76. Kjellmann N-I M. Is there a place for antihistamines in the treatment of perennial asthma? Pediatr Allergy Immunol 1993; 4 (Suppl 4): 38-43.
78. 1-receptor antihistamines in the airways and skin of subjects with asthma. J Allergy Clin Immunol 1993; 91: 1005-1014.
79. 78. Rédier H, Chanez P, De Vos C, Rifaı N, Clauzel A-M, Michel F-B, Godard P. Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma. J Allergy Clin Immunol 1992; 90: 215-224.
80. 79. Walsh G M. The anti-inflammatory effects of cetirizine. Clin Exp Allergy 1994; 24: 81-85.
81. 80. Achterrath-Tuckermann U, Weischer C H, Szelenyi I. Azelastine, a new antiallergic/antiasthmatic agent inhibits PAF-acether-induced platelet aggregation, paw edema and bronchoconstriction. Pharmacology 1988; 36: 265-271.
82. 81. Renesto P, Balloy V, Vargaftig B B, Chignard M. Interference of anti-inflammatory and anti-asthmatic drugs with neutrophil-mediated platelet activation: singularity of azelastine. Br J Pharmacol 1991; 103: 1435-1440.